French contract drug developer Novasep is investing in its U.S. operation, planning to build a new lab in Pennsylvania that will bolster its manufacturing business.
The company is planning to expand its Boothwyn, PA, facility to include a chemical synthesis lab, allowing Novasep to produce small quantities of in-development molecules for preclinical study.
The new lab, slated to come online in May, will sit alongside Novasep's existing contract manufacturing capacity, the company said.
"This U.S. undertaking is part of our 'Back to Basics' strategy we have been implementing for more than two years now," Novasep Synthesis President Thierry Van Nieuwenhove said in a statement. "Novasep is adapting its CMO services to the U.S. market where flexibility and proximity to our customers are required."
The move comes months after Novasep put up $11 million to build an antibody-drug conjugate facility at its Le Mans, France, outpost. That plant will offer bioconjugation services for the production of ADCs, which work by attaching a drug to a homing antibody, allowing for targeted delivery. Novasep expects to bring the facility online in the second quarter.
- read the statement